To browse Academia. The opinions or views expressed in this professional education supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the World Association for Sexual Health.
Dosages, indications, and methods of use for products that are referred to in this supplement by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources.
Because of the differences between in vitro and in vivo systems and between laboratory animal models and clinical data in humans, in vitro and animal data may not necessarily correlate with clinical results. WAS receives abstracts from across the globe and for most of the scholars submitting work English is not their first language. Editors of this special issue refrained from making drastic changes to the received abstracts to ensure authenticity of the author's voice and message.
These are "interesting times" in the fi eld of female sexual function and dysfunction. We are still working without any FDA-approved phamacotherapy for our patient population, so we rely on off-label medication in addition to our behavioral and relationship therapy. In spite of this, we continue to move forward. Unfortunately, we are now faced with those in the fi eld who espouse that FSD is just another "made-up-by-pharmadisease" to sell drugs and make money for their stockholders.
ISSWSH has responded with a position statement that will be circulated among all the societies dedicated to both male and female sexual function. This will be an important effort for our patients, whose voices are not being heard. A global overview of sexual and reproductive health provides reasons for public health, development, and human rights concern.
